HEALTH OF WOMAN. 2019.3(139): 15–20

REFERENCES

1. Practice Committee of the American Society for Reproductive Medicine. 2008. Progesterone supplementation during the luteal phase and in early pregnancyin the treatment of infertility: an educa-tional bulletin. Fertil Steril. 90:150-153.

2. Palomba S, Santagni S, La Sala GB. 2015. Progesterone administration for lutealphase defciency in human reproduction: an old or new issue? J Ovarian Res. 8:77.

3. Van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. 2015. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 7:CD009154.

4. Vaisbuch E, Leong M, Shoham Z. 2012. Progesterone support in IVF: is evidencebased medicine translated to clinical practice? A world-wide web-basedsurvey. Reprod Biomed Online 25:139-145.

5. Fadi Ghazi Mirza, Ameet Patki, Claire Pexman-Fieth. 2016. Применение дидрогестерона на ранних сроках беременности (оригинальный перевод). Репродуктивная эндокринология. 4(30):46-55.

6. Bitsadze VO, Akinshina SV, Hizroeva DH, Makatsariya NA, Stuleva NS, Mashkova TM. 2014. Patogeneticheskoe obosnovanie primeneniya naturalnogo progesterona v akusherskoy praktike. Akusherstvo, ginekologiya i reproduktsiya 2:79-88.

7. Shapiro D, Boostanfar R, Silverberg K, Yanushpolsky EH. 2014. Examining the evidence: progesterone supplementation during fresh and frozen embryo transfer. Reprod Biomed Online. 29:1-14.

8. Ghanem ME, Al-Boghdady LA. 2012. Luteal Phase Support in ART: an Update. http://cdn.intechopen.com/pdfs-wm/41085.pdf (21 October2016, date last accessed).

9. Simonovskaya HYu, Aleev IA; pod red. Radzinskogo VE, 2015. Nevyinashivanie beremennosti: dokazatelnaya baza didrogesterona. Novosti dokazatelnoy meditsinyi didrogesterona po profilaktike i lecheniyu nevyinashivaniya beremennosti. Informatsionnoe pismo. M.: Redaktsiya zhurnala Status Praesens: 24.

10. Schindler AE. 2009. Progestational efects of dydrogesterone in vitro, in vivo andon the human endometrium. Maturitas. 65:3-11.

11. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. 2008. Classifcation and pharmacology of progestins. Maturitas. 61:171-180.

12. Mirza FG, Patki A, Pexman-Fieth C. 2016. Dydrogesterone use in early pregnancy. Gynecol Endocrinol. 32:97-106.

13. Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. 2015. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 186:49-53.

14. Saharkhiz N, Zamaniyan M, Salehpour S, Zadehmodarres S, Hoseini S, Cheraghi L, Seif S, Baheiraei N. 2016. A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization(IVF) cycles. Gynecol Endocrinol. 32:213-217.

15. Zaychenko AV. 2015. Farmakologiya progestinov: chto novogo? (Doklad na Konferentsii «Sovremennyie podhodyi k terapii nevyinashivaniya beremennosti», 14 aprelya 2015 goda, g. Minsk. Meditsinskie novosti. Hronika. 4:43-45.

16. Glujovsky D, Pesce R, Fiszbajn G. et al. 2010. Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes. Cochrane Database Syst Rev. Jan 20; (1): CD006359.

17. Devine K, Richter KS, Widra E A. 2018. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertility and Sterility. 109(2):266-275.

18. Devine K, Bishop LA, Richter KS, Patounakis G, Andriani L, Moon K. 2017. Diminished ovarian reserve as measured by means of baseline follicle-stimulation hormone and antral follicle count is not associated with pregnancy loss in younger in vitro fertilization patients. Fertil Steril. 108(6):980-987.

19. Shih EV. 2010. Kliniko-farmakologicheskie aspektyi primeneniya didrogesterona dlya sohraneniya beremennosti. Akusherstvo, ginekologiya, reproduktsiya. 2:6-9.

20. Schindler AE, Carp H, Druckmann R et al. 2015. European Progestin Club Guidelines for prevention an treatment of threatened or recurrent (habitual) miscarriage with progestogens. Gynecol. Endocrinol. 15:1-3. [PMID: 25976550].

21. Torshin IYu, Gromova OA. 2012. Ekspertnyiy analiz dannyih v molekulyarnoy farmakologi. M.: MTsNMO: 747.

22. Howard Carp. 2015. Obzor klinicheskih issledovaniy primeneniya didrogesterona pri privyichnom nevyinashivanii beremennosti / adaptirovano Shurpyak SA. Zdorove zhenschiny 4(100):80-86.

23. Van der Linden M, Buckingham K, Farquhar C et al. 2012. Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews. Issue 8. Art. No.: CD009154.

24. Podderzhka lyuteinovoy fazyi v tsiklah VRT: dokazatelnaya baza effektivnosti didrogesterona. Reprint (V. Lisitsa). 2018. Medуchnі aspektу zdorov’ya zhіnkу. 4 (117):2-7.

25. A Multicenter Study Comparing the Effcacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization (Lotus I). – URL: https://clinicaltrials. gov/ct2/show/NCT01850030?term=LOTUS+I& rank=1.

26. Tournaye H, Sukhikh G, Kahler E, Griesinger G. 2017. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum. Reprod.:1-9.

27. Griesinger G, Blockeel C, Suhih GT, Patki A, Dhorepatil B, Yang DZ, Chen ZJ, Kahler E, Pexman-Fieth C, Tournaye H. 2018. Peroralnyiy didrogesteron v sravnenii s intravaginalnyim gelem mikronizirovannogo progesterona dlya podderzhki lyuteinovoі fazy pri provedenii EKO: randomizirovannoe klinicheskoe issledovanie. Human Reproduction: 1-10, doi:10.1093/humrep/dey306

28. Griesinger G, Blockeel C, Kahler E, Pexman-Fieth C. 2018. Use of oral dydrogesterone for luteal phase support in fresh IVF an increase in live birth rate: an integrated individual patient data analysis of the LOTUS phase III trial program. ASRM Abstracts. Fertility and Sterility 110(4):90.